Antares Pharma, a provider of self-injection drug delivery technology, has received a US Patent, entitled 'Prefilled Syringe Jet Injector', which will help in protecting its auto injector technology and product pipeline including the VIBEX Medi-Jet device and the VIBEX Quick Shot (QS) technology.
The new patent is intended to protect the use of medicament containing prefilled syringe based auto-injectors, such as those used in OTREXUP and QS T.
Antares Pharma president and chief executive officer Paul Wotton said, "Antares is a pioneer in jet injection technology and this patent along with the Hazardous Agent Injection System patent number 8,480,631 issued this past June, are good examples of intellectual property intended to protect the VIBEX platform as well as any drug/device combination products that could be developed utilizing this type of technology."
The company focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines.
The US Food and Drug Administration (FDA) had already granted marketing approval to the company's OTREXUP (methotrexate) injection to treat adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis.
Additionally, the company is developing VIBEX QS T for testosterone replacement therapy and its technology platforms include VIBEX disposable Medi-Jet, disposable multi-use pen injectors and Vision reusable needle-free injectors marketed as Tjet and Zomajet by Teva Pharmaceutical Industries (Teva) and Ferring Pharmaceuticals (Ferring), respectively.
